Hargreave Hale LTD : Form 8.3 - FORM 8.3

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
16
Hargreave Hale LTD : Form 8.3 - [Clinigen Group plc]

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")

1.         KEY INFORMATION

(a) Full name of discloser: HARGREAVE HALE LIMITED (for Discretionary Clients)
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):      The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and beneficiaries must be named. N/A
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:      Use a separate form for each offeror/offeree CLINIGEN GROUP PLC
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A
(e) Date position held/dealing undertaken:      For an opening position disclosure, state the latest practicable date prior to the disclosure 03 OCTOBER 2017
(f)  In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?      If it is a cash offer or possible cash offer, state "N/A" If YES, specify which: QUANTUM PHARMA PLC

2.         POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)        Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:   ORDINARY 0.1p
    Interests Short positions
Number % Number %
(1) Relevant securities owned and/or controlled: 2,185,861 1.8947    
(2) Cash-settled derivatives:          
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:        
       TOTAL: 2,185,861 1.8947    

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)        Rights to subscribe for new securities (including directors' and other employee options)

Class of relevant security in relation to which subscription right exists:  
Details, including nature of the rights concerned and relevant percentages:  

3.         DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchase/sale   Number of securities Price per unit
ORDINARY PURCHASE 5,450 1131.5242p

 (b)       Cash-settled derivative transactions

Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit
NONE          

(c)        Stock-settled derivative transactions (including options)

(i)         Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit
NONE              

(ii)        Exercise

Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable)
NONE      

4.         OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.  If there are no such agreements, arrangements or understandings, state "none"
  NONE  

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)  the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none"
  NONE  

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached? NO
Date of disclosure: 04 OCTOBER 2017
Contact name: DAVID CLUEIT HARGREAVE HALE LTD
Telephone number: 01253 754739

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

IVD Reagents Market Growth Expected to Reach $55.3 Billion

Updated Category News Views 120

Growth Forecast for the IVD Reagents Market The global In Vitro Diagnostic (IVD) reagents market is on an impressive trajectory to reach nearly USD 55.3 billion by 2029. The demand for IVD reagents has surged, driven by numerous factors such as a rising prevalence of chronic and infectious diseases, alongside a growing emphasis on preventive healthcare. In 2022, the IVD...

Continue Reading
Cayuga Centers Expands Leadership Team with New Appointments

Updated Category News Views 235

Exciting Growth at Cayuga Centers With New Board Members Cayuga Centers is thrilled to announce the welcoming of nine new members to its Board of Trustees. This addition of distinguished professionals promises to enhance the agency's leadership and the resources it employs to support children, youth, and families across the nation. Each of these new board members brings a...

Continue Reading
Elements Massage Celebrates Skin Care Awareness Month with Tips

Updated Category News Views 204

Elements Massage Celebrates National Skin Care Awareness Month As National Skin Care Awareness Month comes to an end, Elements Massage, the nation's leading massage therapy concept, is highlighting skincare and wellness. Innovative Skincare Services Elements Massage has introduced enhanced skincare services in collaboration with Sanitas Skincare. This partnership marks...

Continue Reading
The Growth Journey of Danaher Stock Over the Past Decade

Updated Category News Views 106

Understanding Danaher's Stock Growth Danaher Corporation (NYSE: DHR) has consistently demonstrated robust performance in the stock market. With an average annual return of 13.82%, it has outpaced the market by 1.08% over the past decade. Currently, Danaher boasts a commendable market capitalization of $163.05 billion. Investment Insight: What If You Invested $100? Let’s...

Continue Reading
Matthew A. Cartwright Returns to Munley Law to Elevate Advocacy

Updated Category News Views 197

Matthew A. Cartwright Rejoins Munley Law as Of Counsel The six-term Congressman brings decades of legal expertise and legislative accomplishments back to the Pennsylvania personal injury law firm. MUNLEY Law is excited to announce the return of former U.S. Representative Matthew A. Cartwright as Of Counsel. Following a commendable 12 years in Congress, Cartwright brings a...

Continue Reading